iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML
Andrew Wei et al.
BTK inhibitors for relapsed mantle cell lymphoma: the new standard of care?
Information on the iwCLL 2017 meeting
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
A next-generation CD33-directed ADC for AML